Background / Study Design

BDB001 is an immune modulator capable of generating both innate and adaptive immunity against tumors

Safety and Efficacy Results

BDB001 combined with pembrolizumab was well tolerated without a DLT with a favorable efficacy profile

Efficacy and Pharmacodynamic Results

Clinical responses observed in subjects with various tumor types

Discussion / Conclusions

Seventy and Eight Biopharmaceuticals' systemic delivery of TLR 7/8 dual agonist BDB001 is first-in-class

BDB001 was delivered safety intravenously in combination with pembrolizumab

Grade 3 or 4 grade CRS or IRR, as deemed by the investigators, were seen in 16% of subjects. Since these subjects' AEs occurred after the first infusion of BDB001 and pembrolizumab and all subjects resolved quickly without long-term sequelae.

Note: Subject BDB001 combined with pembrolizumab associated with clinical responders no significant increase in inflammatory cytokine levels.

Seventy and Eight Biopharmaceuticals' systemic delivery of TLR 7/8 dual agonist BDB001 is first-in-class

BDB001 was delivered safety intravenously in combination with pembrolizumab

Grade 3 or 4 grade CRS or IRR, as deemed by the investigators, were seen in 16% of subjects. Since these subjects' AEs occurred after the first infusion of BDB001 and pembrolizumab and all subjects resolved quickly without long-term sequelae.

Note: Subject BDB001 combined with pembrolizumab associated with clinical responders no significant increase in inflammatory cytokine levels.

Seventy and Eight Biopharmaceuticals' systemic delivery of TLR 7/8 dual agonist BDB001 is first-in-class

BDB001 was delivered safety intravenously in combination with pembrolizumab

Grade 3 or 4 grade CRS or IRR, as deemed by the investigators, were seen in 16% of subjects. Since these subjects' AEs occurred after the first infusion of BDB001 and pembrolizumab and all subjects resolved quickly without long-term sequelae.

Note: Subject BDB001 combined with pembrolizumab associated with clinical responders no significant increase in inflammatory cytokine levels.

Seventy and Eight Biopharmaceuticals' systemic delivery of TLR 7/8 dual agonist BDB001 is first-in-class

BDB001 was delivered safety intravenously in combination with pembrolizumab

Grade 3 or 4 grade CRS or IRR, as deemed by the investigators, were seen in 16% of subjects. Since these subjects' AEs occurred after the first infusion of BDB001 and pembrolizumab and all subjects resolved quickly without long-term sequelae.

Note: Subject BDB001 combined with pembrolizumab associated with clinical responders no significant increase in inflammatory cytokine levels.